APA (7th ed.) Citation

Wawruszak, A., Luszczki, J., Bartuzi, D., Kalafut, J., Okon, E., Czerwonka, A., & Stepulak, A. (2025). Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: In silico, in vitro, and in vivo studies. Journal of Enzyme Inhibition & Medicinal Chemistry, 40(1), 1. https://doi.org/10.1080/14756366.2025.2458554

Chicago Style (17th ed.) Citation

Wawruszak, Anna, Jarogniew Luszczki, Damian Bartuzi, Joanna Kalafut, Estera Okon, Arkadiusz Czerwonka, and Andrzej Stepulak. "Selisistat, a SIRT1 Inhibitor, Enhances Paclitaxel Activity in Luminal and Triple-negative Breast Cancer: In Silico, in Vitro, and in Vivo Studies." Journal of Enzyme Inhibition & Medicinal Chemistry 40, no. 1 (2025): 1. https://doi.org/10.1080/14756366.2025.2458554.

MLA (9th ed.) Citation

Wawruszak, Anna, et al. "Selisistat, a SIRT1 Inhibitor, Enhances Paclitaxel Activity in Luminal and Triple-negative Breast Cancer: In Silico, in Vitro, and in Vivo Studies." Journal of Enzyme Inhibition & Medicinal Chemistry, vol. 40, no. 1, 2025, p. 1, https://doi.org/10.1080/14756366.2025.2458554.